Flash Finance

Alpa Laboratories LimitedALPACorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹53.46
MCap ₹112 Cr · P/E 25.7
Alpa Laboratories Limited — Stock analysis & AI research Alpa Laboratories Limited — Seasonality — best & worst months Alpa Laboratories Limited — Technical setup — score, trend, support & resistance Alpa Laboratories Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹24 Cr
Sales · Jun 2026
+25.2% YoY
₹-4 Cr
Operating Profit · Jun 2026
-1033.5% YoY
-16.5%
OPM % · Jun 2026
-850.0% YoY
₹1 Cr
Net Profit · Jun 2026
-91.7% YoY
₹0.49
EPS · Jun 2026
-91.2% YoY

📝 Alpa Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Alpa Laboratories Limited reported revenue of ₹24 crore for the quarter ended June 2026 (Q1 FY27), up 25.2% from ₹19 crore in the same quarter last year, and down 23.8% sequentially over the March 2026 quarter.

Net profit fell 91.7% year-on-year to ₹1 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹0.49.

Operating profit stood at ₹-4 crore — an operating margin (OPM) of -16.5%, compared with 2.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Alpa Laboratories Limited posted revenue of ₹106 crore, a decline of 5.9% over FY25, with a net profit of ₹15 crore (down 22.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹111 crore with a net profit of ₹4 crore.

Valuation snapshot

At the current price of ₹53.46, ALPA has a market capitalisation of ₹112 crore and a trailing P/E of about 25.7.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 18th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 57.19%, foreign institutional investors (FIIs) 0.38%, domestic institutional investors (DIIs) 0.00%, public shareholders 42.43% of Alpa Laboratories Limited.

Promoter holding slipped from 57.29% to 57.19% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹112 Cr
Current Price ?
₹53.5
P/E ?
25.71above ind
Industry P/E ?
21.30
P/B ?
0.60
P/S ?
1.02
P/FCF ?
18.75
Enterprise Value ?
₹115 Cr
EV/EBITDA ?
62.07
PEG ?
4.28
Earnings Yield ?
0.2%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹111 Cr
OPM ?
1.7%
Profit after tax (TTM) ?
₹4 Cr
EPS (TTM) ?
₹2.08
ROCE ?
9.0%
ROE ?
2.4%
ROA ?
1.8%
Growth
Sales — latest qtr ?
₹24 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
25.2%
YoY qtr profit growth ?
-91.7%
Sales growth (3y) ?
4%
Sales growth (5y) ?
2%
Profit growth (3y) ?
6%
Profit growth (5y) ?
24%
Financial Health
Debt ?
₹3 Cr
Debt to Equity ?
0.02
Interest Coverage ?
1.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
57.19%
Change in promoter holding ?
-0.10%
Pledged percentage ?
N/A
Market
Return 3 months ?
-21.9%
Return 6 months ?
-22.3%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 272925322724212526401926293124 +25.2% -23.8%
Operating Profit 39-132413100124-4 -1033.5% -209.9%
Other Income 3-1434457921231-06 -51.7% +3705.0%
Interest 000000000004000 +132.2% -26.5%
Depreciation 010011111110101 +30.2% +227.5%
Profit Before Tax 58365751092120231 -91.7% -68.1%
Net Profit 553654589-2120211 -91.7% -29.0%
EPS 2.452.091.442.752.171.692.423.654.23-1.015.590.050.900.660.49 -91.2% -25.8%
OPM % 9.6% 31.7% -4.5% 10.3% 8.9% 14.9% 2.5% 13.3% 2.8% 0.5% 2.2% 2.7% 5.2% 11.5% -16.5% -850.0% -243.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹112 Cr ₹106 Cr ₹111 Cr -5.9%
Operating Profit ₹5 Cr ₹6 Cr ₹2 Cr +30.2%
OPM % 4.26% 5.90% 1.68% +38.5%
NPM % 17.40% 14.33% 3.96% -17.6%
Other Income ₹23 Cr ₹16 Cr ₹10 Cr -32.5%
Depreciation ₹2 Cr ₹1 Cr ₹2 Cr -34.0%
Interest ₹0 Cr ₹4 Cr ₹4 Cr +1713.9%
EBIT ₹3 Cr ₹5 Cr ₹0 Cr +84.8%
PBT ₹26 Cr ₹17 Cr ₹6 Cr -35.1%
Tax ₹0 Cr ₹-0 Cr ₹-0 Cr -7895.0%
Net Profit ₹20 Cr ₹15 Cr ₹4 Cr -22.5%
EPS ₹9.29 ₹7.20 ₹2.10 -22.5%
Material Cost ₹28 Cr ₹47 Cr ₹56 Cr +69.0%
Employee Cost ₹7 Cr ₹10 Cr ₹11 Cr +55.6%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 21212121 +0.0%
Reserves 114131150165 +10.0%
Borrowings 2503 —
Other Liabilities 30255153 +3.9%
Total Liabilities 167182223242 +8.5%
Fixed Assets 7112120 -4.8%
CWIP 0000 —
Investments 7898118142 +20.3%
Other Assets 82738480 -4.8%
Total Assets 167182223242 +8.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 941810 -44.4%
Cash from Investing Activity 2-13-12-12 +0.0%
Cash from Financing Activity -43-52 +140.0%
Net Cash Flow 7-711 +0.0%
Free Cash Flow 8-376 -14.3%
CFO/OP 155%85%466%389% -16.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 184138155141 -9.0%
Inventory Days 84739273 -20.7%
Days Payable 100639798 +1.0%
Cash Conversion Cycle 168149150116 -22.7%
Working Capital Days 152135110537 +388.2%
ROCE % 12%15%16%9% -43.8%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 57.29%57.29%57.29%57.19% -0.2%
FIIs 0.36%0.35%0.36%0.38% +5.6%
DIIs 0.00%0.00%0.00%0.00% —
Public 42.34%42.36%42.35%42.43% +0.2%
No. of Shareholders 18,85118,54218,23617,900 -1.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Alpa Laboratories Limited's revenue in Q1 FY27?
Alpa Laboratories Limited reported revenue of ₹24 crore for the quarter ended June 2026 (Q1 FY27), up 25.2% from ₹19 crore in the same quarter last year, and down 23.8% sequentially over the March 2026 quarter.
What was Alpa Laboratories Limited's net profit in Q1 FY27?
Net profit fell 91.7% year-on-year to ₹1 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹0.49.
What is ALPA's market capitalisation and P/E ratio?
At the current price of ₹53.46, ALPA has a market capitalisation of ₹112 crore and a trailing P/E of about 25.7.
Who owns Alpa Laboratories Limited? (shareholding pattern)
As of Mar 2026, promoters held 57.19%, foreign institutional investors (FIIs) 0.38%, domestic institutional investors (DIIs) 0.00%, public shareholders 42.43% of Alpa Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI